Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manfred Hauben

Showing results (61-70 of 112) with videos related to

Pageof 12
Sort By:
Clinical Therapeutics|November 2, 2023
Potential Signals of COVID-19 as an Effect Modifier of Adverse Drug ReactionsManfred Hauben, Eric Hung, Yan Chen
Clinical Pharmacology and Therapeutics|March 21, 2020
Response to "Pharmacovigilance 2030: Invited Commentary for the January 2020 'Futures' Edition"Manfred Hauben, William W Gregory, Patrick Caubel
Pharmacoepidemiology and Drug Safety|June 29, 2006
Reports of hyperkalemia after publication of RALES--a pharmacovigilance studyManfred Hauben, Lester Reich, Charles M Gerrits
Therapeutic Advances in Drug Safety|August 29, 2017
A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionalityFrançois Maignen, Manfred Hauben, Jean-Michel Dogné
Therapeutic Advances in Drug Safety|February 17, 2017
An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactionsManfred Hauben, Eric Hung, Wen-Yaw Hsieh
Drug Safety|April 3, 2012
Defining 'surveillance' in drug safetyJeffrey K Aronson, Manfred Hauben, Andrew Bate
Drugs - Real World Outcomes|October 18, 2016
Seasonal and Geographic Variation in Adverse Event ReportingOsvaldo Marrero, Eric Y Hung, Manfred Hauben
Clinical Therapeutics|August 14, 2024
Current Approaches in Postapproval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published LiteratureJuan Joanne Wu, Manfred Hauben, Muhammad Younus
Drug Safety|September 15, 2006
What counts in data mining?Manfred Hauben, Vaishali K Patadia, David Goldsmith
European Journal of Gastroenterology & Hepatology|December 1, 2007
Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysisManfred Hauben, Ferdinando Vegni, Lester Reich, et al.
Pageof 12

Showing results (61-70 of 112) with videos related to

Sort By:
Pageof 12
Clinical Therapeutics|November 2, 2023
Potential Signals of COVID-19 as an Effect Modifier of Adverse Drug ReactionsManfred Hauben, Eric Hung, Yan Chen
Clinical Pharmacology and Therapeutics|March 21, 2020
Response to "Pharmacovigilance 2030: Invited Commentary for the January 2020 'Futures' Edition"Manfred Hauben, William W Gregory, Patrick Caubel
Pharmacoepidemiology and Drug Safety|June 29, 2006
Reports of hyperkalemia after publication of RALES--a pharmacovigilance studyManfred Hauben, Lester Reich, Charles M Gerrits
Therapeutic Advances in Drug Safety|August 29, 2017
A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionalityFrançois Maignen, Manfred Hauben, Jean-Michel Dogné
Therapeutic Advances in Drug Safety|February 17, 2017
An exploratory factor analysis of the spontaneous reporting of severe cutaneous adverse reactionsManfred Hauben, Eric Hung, Wen-Yaw Hsieh
Drug Safety|April 3, 2012
Defining 'surveillance' in drug safetyJeffrey K Aronson, Manfred Hauben, Andrew Bate
Drugs - Real World Outcomes|October 18, 2016
Seasonal and Geographic Variation in Adverse Event ReportingOsvaldo Marrero, Eric Y Hung, Manfred Hauben
Clinical Therapeutics|August 14, 2024
Current Approaches in Postapproval Vaccine Safety Studies Using Real-World Data: A Systematic Review of Published LiteratureJuan Joanne Wu, Manfred Hauben, Muhammad Younus
Drug Safety|September 15, 2006
What counts in data mining?Manfred Hauben, Vaishali K Patadia, David Goldsmith
European Journal of Gastroenterology & Hepatology|December 1, 2007
Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysisManfred Hauben, Ferdinando Vegni, Lester Reich, et al.
Pageof 12